Literature DB >> 10760695

Selective inhibition of hepatoma cells using diphtheria toxin A under the control of the promoter/enhancer region of the human alpha-fetoprotein gene.

M Kunitomi1, E Takayama, S Suzuki, T Yasuda, K Tsutsui, K Nagaike, S Hiroi, T Tadakuma.   

Abstract

We constructed a plasmid containing human alpha-fetoprotein (AFP) promoter/enhancer to direct the cell type-specific expression of diphtheria toxin fragment A (DTA), designated as pAF-DTA, to AFP-producing hepatocellular carcinoma cells. The transfection was carried out with cationic liposomes (DMRIE-C) and the expression of the DTA gene was confirmed by a northern blot analysis. When pAF-DTA was transfected, the growth of AFP-positive HuH-7 cells was inhibited, whereas growth inhibition was not observed in AFP-negative MKN45 cells. In this experiment, the secretion of AFP was similarly suppressed, but the secretion of carcinoembryonic antigen from MKN45 was not altered. pAF-DTA could also exert its growth inhibitory effect on PLC, a cell line with a low level of AFP. However, no inhibitory effect of pAF-DTA was observed on the proliferation of primary hepatocyte cells. Furthermore, transfection experiments in which HuH-7 and splenic stromal cells were co-cultured revealed the growth inhibition by pAF-DTA to be selective in HuH-7 cells. Finally, the growth of HuH-7 transplanted on BALB/c nu/nu mice was inhibited by the direct injection of pAF-DTA/liposome complex into a tumor mass. These results suggest that use of pAF-DTA may be potentially useful as a novel approach for the selective treatment of tumor cells producing AFP even at low levels, without affecting other types of cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10760695      PMCID: PMC5926372          DOI: 10.1111/j.1349-7006.2000.tb00951.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  32 in total

1.  Expression of the diphtheria toxin A-chain coding sequence under the control of promoters and enhancers from immunoglobulin genes as a means of directing toxicity to B-lymphoid cells.

Authors:  I H Maxwell; L M Glode; F Maxwell
Journal:  Cancer Res       Date:  1991-08-15       Impact factor: 12.701

2.  Elevation of lymphocyte and hematopoietic stem cell numbers in mice transgenic for human granulocyte CSF.

Authors:  T Yamada; H Kaneko; K Iizuka; Y Matsubayashi; Y Kokai; J Fujimoto
Journal:  Lab Invest       Date:  1996-02       Impact factor: 5.662

3.  Tissue-specific expression of herpes simplex virus thymidine kinase gene delivered by adeno-associated virus inhibits the growth of human hepatocellular carcinoma in athymic mice.

Authors:  H Su; R Lu; J C Chang; Y W Kan
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-09       Impact factor: 11.205

4.  Herpes simplex virus thymidine kinase/ganciclovir-mediated apoptotic death of bystander cells.

Authors:  W Hamel; L Magnelli; V P Chiarugi; M A Israel
Journal:  Cancer Res       Date:  1996-06-15       Impact factor: 12.701

5.  Gene therapy for hepatoma cells using a retrovirus vector carrying herpes simplex virus thymidine kinase gene under the control of human alpha-fetoprotein gene promoter.

Authors:  A Ido; K Nakata; Y Kato; K Nakao; K Murata; M Fujita; N Ishii; T Tamaoki; H Shiku; S Nagataki
Journal:  Cancer Res       Date:  1995-07-15       Impact factor: 12.701

6.  Adenovirus-mediated prodrug gene therapy for carcinoembryonic antigen-producing human gastric carcinoma cells in vitro.

Authors:  T Tanaka; F Kanai; S Okabe; Y Yoshida; H Wakimoto; H Hamada; Y Shiratori; K Lan; M Ishitobi; M Omata
Journal:  Cancer Res       Date:  1996-03-15       Impact factor: 12.701

7.  Regulated expression of a diphtheria toxin A-chain gene transfected into human cells: possible strategy for inducing cancer cell suicide.

Authors:  I H Maxwell; F Maxwell; L M Glode
Journal:  Cancer Res       Date:  1986-09       Impact factor: 12.701

8.  Adenovirus-mediated gene therapy of hepatocellular carcinoma using cancer-specific gene expression.

Authors:  S Kaneko; P Hallenbeck; T Kotani; H Nakabayashi; G McGarrity; T Tamaoki; W F Anderson; Y L Chiang
Journal:  Cancer Res       Date:  1995-11-15       Impact factor: 12.701

9.  Cell-specific enhancer activity in a far upstream region of the human alpha-fetoprotein gene.

Authors:  K Watanabe; A Saito; T Tamaoki
Journal:  J Biol Chem       Date:  1987-04-05       Impact factor: 5.157

10.  Cell lineage ablation in transgenic mice by cell-specific expression of a toxin gene.

Authors:  R D Palmiter; R R Behringer; C J Quaife; F Maxwell; I H Maxwell; R L Brinster
Journal:  Cell       Date:  1987-07-31       Impact factor: 41.582

View more
  7 in total

1.  Targeted tumor gene therapy based on loss of IGF2 imprinting.

Authors:  Yuqin Pan; Bangshun He; Tao Li; Chan Zhu; Lirong Zhang; Bo Wang; Yongfei Xu; Lili Qu; Andrew R Hoffman; Shukui Wang; Jifan Hu
Journal:  Cancer Biol Ther       Date:  2010-08-21       Impact factor: 4.742

Review 2.  Gene therapy of liver cancer.

Authors:  Ruben Hernandez-Alcoceba; Bruno Sangro; Jesus Prieto
Journal:  World J Gastroenterol       Date:  2006-10-14       Impact factor: 5.742

3.  Survival and recurrences after hepatic resection or radiofrequency for hepatocellular carcinoma in cirrhotic patients: a multivariate analysis.

Authors:  Marco Montorsi; Roberto Santambrogio; Paolo Bianchi; Matteo Donadon; Eliana Moroni; Antonino Spinelli; Mara Costa
Journal:  J Gastrointest Surg       Date:  2005-01       Impact factor: 3.452

4.  Development of a nonintegrating Rev-dependent lentiviral vector carrying diphtheria toxin A chain and human TRAF6 to target HIV reservoirs.

Authors:  Z Wang; Z Tang; Y Zheng; D Yu; M Spear; S R Iyer; B Bishop; Y Wu
Journal:  Gene Ther       Date:  2010-04-22       Impact factor: 5.250

Review 5.  Toxin-based therapeutic approaches.

Authors:  Assaf Shapira; Itai Benhar
Journal:  Toxins (Basel)       Date:  2010-10-28       Impact factor: 4.546

6.  Development of gene therapy using prostate-specific membrane antigen promoter/enhancer with Cre Recombinase/LoxP system for prostate cancer cells under androgen ablation condition.

Authors:  Shusei Ikegami; Takushi Tadakuma; Satoshi Suzuki; Ichiro Yoshimura; Tomohiko Asano; Masamichi Hayakawa
Journal:  Jpn J Cancer Res       Date:  2002-10

Review 7.  Targeted Diphtheria Toxin-Based Therapy: A Review Article.

Authors:  Fatemeh Shafiee; Marc G Aucoin; Ali Jahanian-Najafabadi
Journal:  Front Microbiol       Date:  2019-10-18       Impact factor: 5.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.